The post-marketing surveillance (PMS) of drugs is necessary because of the
limited size of the clinical safety database at the time of marketing. The
principal hypothesis-generating methods of PMS are spontaneous reporting (e
.g. the yellow card) and Prescription Event Monitoring. These methods are d
iscussed in this chapter and certain basic pharmacoepidemiological issues t
hat are relevant are briefly reviewed.